About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Virus expert Dr. Ron Diskin is fighting COVID-19 by expediting two investigations that are based on his studies of similar animal-borne viruses and the Ebola vaccine.
March 15, 2020
Prof. Gabi Barbash, former Director General of Israel’s Ministry of Health and Director of the Weizmann Institute’s Bench-to-Bedside Program, answers questions about the public health implications of the coronavirus outbreak.
March 15, 2020
Legendary Weizmann scientist Prof. Ruth Arnon, whose universal flu vaccine is in late-stage clinical trials, discusses approaches to COVID-19 and other coronaviruses – now and in the future.
March 14, 2020
Dr. Noam Stern-Ginossar is investigating the way viruses are able to successfully commandeer our cells in the first place. Her innovative methods, and the resulting insights, could lead to treatments for viruses such as COVID-19.
March 12, 2020
Even in 2020, with all we know about health and nutrition, heart disease is still the leading cause of death in America, accounting for one in four mortalities. Fortunately, the Weizmann Institute of Science is taking multiple approaches to understanding and treating this too-common killer. February is American Heart Month – and we’d love to share our very latest research with you.
While there are several vital heart-related projects underway at the Institute, the lab of leading researcher Prof. Eldad Tzahor recently made a significant breakthrough: discovering that a non-toxic dye actually helps repair damaged heart tissue, such as the scarring that occurs after a heart attack.
Dr. Ron Diskin and his team engineered a molecule that could lead to treatments for viruses that cross over from animals to humans – and may even prevent the infection in the first place. They are working to apply it to coronavirus.
February 02, 2020
Immunotherapies, which harness the immune system to fight disease, are revolutionizing treatments for many types of cancer. Having made significant breakthroughs in the field, Weizmann Institute of Science researchers are now exploring ways to apply immunotherapy to conditions other than cancer, including neurodegenerative diseases like Alzheimer’s. Prof. Ido Amit of the Department of Immunology is advancing this research by developing sophisticated tools and technologies to investigate the immune system’s role in neurodegenerative diseases.
Acute myeloid leukemia (AML), a cancer of the blood and bone marrow, is usually only diagnosed at an advanced stage, at which point it requires aggressive treatment. Although AML is a relatively rare disease, accounting for just 1.8 percent of cancer deaths in the U.S., its incidence is expected to increase as the population ages. The average age of diagnosis is 68.
What better way to begin a new year than meeting some of the Weizmann Institute’s new scientists?
Every year, the Institute recruits several talented young researchers, each of whom is already a standout in their field. One reason the selection process is so particular is that, once on campus, the scientists are given everything they need to kick off their careers, such as a custom-built lab that has the equipment required for each specialty. The results speak for themselves.
©2020 American Committee for the Weizmann Institute of Science